Neurelis, Inc. https://validator.w3.org/feed/docs/rss2.html Home Leadership Our Pipeline Our Product NEURELIS TO HIGHLIGHT DATA FROM A STUDY OF DIAZEPAM NASAL SPRAY IN PEDIATRIC PATIENTS AT THE CHILD NEUROLOGY SOCIETY ANNUAL MEETING NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING Board of Directors NEURELIS PROVIDES BUSINESS UPDATE HIGHLIGHTING TRANSFORMATIONAL 2025 RESULTS NEURELIS TO PARTICIPATE IN SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT California Declaration Careers NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company Neurelis Files New Drug Application With The FDA For VALTOCO™ (Diazepam Nasal Spray), An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients Neurelis Expands Worldwide Patent Portfolio with Latest Issuance in Japan Neurelis Receives FDA Orphan Drug Designation for NRL-1 in the Treatment of Acute Repetitive Seizures Neurelis Initiates Pivotal Clinical Program for NRL-1 in the Treatment of Acute Repetitive Seizures Neurelis Finalizes Series A Financing to Advance Lead Program to NDA Filing Neurelis Recieves FDA Fast Track Designation for NRL-1 Neurelis Completes Series B Financing NEURELIS ANNOUNCES COMPLETION OF SENIOR MANAGEMENT TEAM BUILDOUT TO SUPPORT THE ANTICIPATED COMMERCIAL LAUNCH OF VALTOCO™ Neurelis Announces That Intravail® Licensee ARS Pharmaceuticals Intranasal Epinephrine Program Given Fast Track Designation Neurelis Announces First Product Approved Using The Company’s Intravail® Platform INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS, SECURES $20M FINANCING FROM DEERFIELD MANAGEMENT Neurelis Announces Two Poster Presentations At The Annual Meeting Of The American Academy Of Neurology UPSHER-SMITH LABORATORIES ANNOUNCES THE LAUNCH OF TOSYMRA™ USING NEURELIS’ INTRAVAIL® TECHNOLOGY NEURELIS ANNOUNCES THREE POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE CHILD NEUROLOGY SOCIETY NEURELIS ANNOUNCES NINE POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY NEURELIS ANNOUNCES TOTAL OF NINE POSTER PRESENTATIONS FOR THE AANN, AMCP, AND AAN ANNUAL MEETINGS Neurelis Announces 12 Poster Presentations for the Annual Meeting of the American Epilepsy Society NEURELIS ANNOUNCES THAT INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS’ INTRANASAL EPINEPHRINE PRODUCT, DEMONSTRATES BIOEQUIVALENT EXPOSURE TO EPINEPHRINE INJECTORS NEURELIS ANNOUNCES RAPID AND BROAD PAYER COVERAGE OF THE COMPANY’S FLAGSHIP PRODUCT, VALTOCO® (DIAZEPAM NASAL SPRAY) Neurelis Announces Program to Investigate the Safety and Pharmacokinetics of VALTOCO® (diazepam nasal spray) in Children Aged 2 to 5 Neurelis Announces Four Poster Presentations for the Joint Meeting of the International Child Neurology Association and Child Neurology Society Neurelis Announces FDA Approval of Extended Expiration Dating for VALTOCO® (diazepam nasal spray) Neurelis Announces National Wholesale and Retailer Chains and Independent Pharmacies Are Now Stocking VALTOCO® (diazepam nasal spray) Neurelis Completes Pre-IND Meeting With FDA to Establish Clinical Development Program for NRL-4 in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar 1 Mania in Adults NEURELIS TO PRESENT AT SVB LEERINK 9th ANNUAL GLOBAL HEALTHCARE CONFERENCE NEURELIS ANNOUNCES FDA APPROVAL FOR SEIZURE RESCUE TREATMENT VALTOCO® (DIAZEPAM NASAL SPRAY) THAT INCORPORATES THE SCIENCE OF INTRAVAIL® FOR CONSISTENT AND RELIABLE ABSORPTION NEURELIS ANNOUNCES COMMERCIAL AVAILABILITY OF VALTOCO® (DIAZEPAM NASAL SPRAY) FOR SEIZURE CLUSTER RESCUE NEURELIS ANNOUNCES CLOSE OF $114 MILLION SERIES D FINANCING ROUND TO ADVANCE NEUROSCIENCE FOCUS NEURELIS ANNOUNCES 16 POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY NEURELIS ANNOUNCES ADDITION OF BRITTANY BRADRICK AS CFO AND EXPANSION OF LEADERSHIP TEAM AND BOARD OF DIRECTORS NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE CHILD NEUROLOGY SOCIETY NEURELIS INITIATES STUDY OF VALTOCO® (diazepam nasal spray) IN CHILDREN WITH SEIZURE CLUSTERS AGED TWO TO FIVE NEURELIS SECURES SENIOR TERM LOAN FACILITY OF UP TO $150 MILLION FROM ORBIMED NEURELIS ANNOUNCES ACQUISITION OF RIGHTS TO PORTFOLIO OF NEW CHEMICAL ENTITY (NCE) COMPOUNDS TARGETING CEREBRAL CAVERNOUS MALFORMATIONS, A RARE CNS DISORDER NEURELIS ANNOUNCES FIVE POSTER PRESENTATIONS FOR THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS FOR THE ANNUAL MEETING OF THE ACADEMY OF MANAGED CARE PHARMACY